Skip to main content
Uncategorized

The UB licenses a patent for the treatment of cancer

By 30 de November de 2005November 18th, 2020No Comments
< Back to news
 30.11.2005

The UB licenses a patent for the treatment of cancer

The Universitat de Barcelona (UVB, University of Barcelona), through the of the Bosch i Gimpera Foundation, has signed a new licensing contract with the enterprise for one of its chemical compound patents for the treatment of cancer.

The invention, patented by UB researchers, claims that the natural product called Antitumoral 514 is an active agent against several kinds cancer cell lines, including lung and breast cancer and some kinds of leukaemia. In addition, the knowledge developed will allow a broadening of the application domain of the product to other kinds of cancer and the synthesis of new derivative compounds which may also be active for the treatment of this group of diseases.

The patent, named “Cyclic dipsipeptide as a chemotherapeutic agent against cancer”, is the result of joint research performed by the group directed by Ricardo Pérez, at the Dept. of Pathology and Experimental Therapeutics, at the Medical School of Bellvitge, and Ernest Giralt, who leads a research team devoted to Design, synthesis and structure of peptides and proteins at the Institute of Biomedical Research, which is located at the Parc Científic de Barcelona/ Barcelona Sceince Park). Furthermore, Beatriz Montaner, at the Dept. of Pathology and Experimental Therapeutics, and Marc Martinell and Marta Vilaseca, at the Institute of Biomedical Research also figure as inventors.

The agreement, negotiated between the Innovation Centre of the Bosch i Gimpera Foundation, will allow the research project of thhese groups to receive continued funding and will also allow the la UB and the inventors to receive a percentage of the profit that Cancer Research Technology obtains through commercialisation of the invention.

Cancer Research Technology is a London-based enterprise specialised in technology transfer in the field of oncology. Its goal is to ensure that cutting edge discoveries in cancer research are developed to treat those who suffer from this disease. Cancer Research Technology commercialises technologies developed by Cancer Research UK as well as others of many other leading international institutes in oncology.